Anzeige
Mehr »
Login
Freitag, 18.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Trumps Dekret beschleunigt Antimon-Boom - Wird Global Tactical der nächste Highflyer für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
54 Leser
Artikel bewerten:
(0)

Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc

Finanznachrichten News

NEW YORK, March 13 /PRNewswire/ -- Jina Ventures is pleased to announce the acquisition of clinical pharmacology and research company, Swiss Pharma Contract (SPC) by leading contract research organization, Covance Inc . Jina Ventures was the exclusive financial advisor to SPC in the transaction, which provides Covance with the facilities and services of Basel, Switzerland area-based SPC.

"We are thrilled to have been an integral part of a deal that we believe adds real value to a well-established global player," said Ron Shah, Managing Partner, Jina Ventures. "There were bids for SPC from several global clinical research organizations, but Covance presented the most compelling opportunity for strategic long-term growth for SPC."

SPC was seed-funded by Novartis Venture Fund in 1998, and provides Phase I clinical trials to leading pharmaceutical clients and biotechnology companies in Europe, the United States and Asia. SPC's leadership includes Dr. Rolf Pokorny and Dr. Michael Seiberling, two industry veterans in the field of Phase I clinical trials.

Jina Ventures invigorated the M&A process by using a customized global auction, which resulted in interest from 14 leading companies, based in Europe, Asia and the U.S. As worldwide M&A volume has declined over the last 12 months, auctions continue to be an effective way to utilize global competitiveness to drive deal value and strategic fit.

On the heels of this transaction, Jina Ventures is poised for major growth in 2009, targeting the close of a second life sciences M&A transaction by mid-year and the launch of its second fund of US$200 million later this year. Jina's second fund is a cross border private equity fund designed to leverage global competitiveness for its portfolio companies in the US and India.

About Jina Ventures:

Founded in 2003, Jina Ventures is a New York-based private equity and M&A advisory firm. Over the past 6 years, Jina Ventures has grown into a full service private equity practice, with both principal investing and cross-border mergers and acquisitions. In addition to New York City, Jina Ventures also has offices in Mumbai, Tokyo, Bangkok and Singapore. More information can be found at http://www.jinaventures.com/.

© 2009 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.